GHRP-6 vs Semaglutide
Well Studied vs FDA Approved
monitor Mechanism-based · 47% Both GHRP-6 and Semaglutide affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine).
Molecular Data
GHRP-6 Semaglutide
Weight 873 Da 4,113.64 Da
Half-life 15-60 minutes ~7 days (168 hours)
Chain 6 amino acids 31 amino acids
Type Synthetic hexapeptide GLP-1 receptor agonist
Key Benefits
GHRP-6
01 Potent stimulation of natural growth hormone release
02 Significant increase in appetite (beneficial for bulking/weight gain)
03 Enhanced muscle growth through elevated GH and IGF-1
04 Improved fat metabolism and body composition
05 Cardioprotective effects observed in research
06 Enhanced recovery from exercise and injury
07 Cytoprotective and anti-inflammatory properties
08 Maintains natural GH pulsatile release
Semaglutide
01 15-20% average body weight reduction
02 Established cardiovascular protection
03 Convenient once-weekly dosing options
04 Comprehensive safety data from extensive trials
05 Flexible injectable and oral formulations
Dosing Protocols
GHRP-6
100-300 mcg per injection / 2-3 times daily (morning, post-workout optional, before bed)
GH optimization 100 mcg 2-3x daily
Enhanced results 200-300 mcg 2-3x daily
With GHRH (synergy) 100 mcg each 2-3x daily
Appetite/bulking 100-200 mcg Before meals
Semaglutide
0.25mg starting, titrate to 1-2.4mg weekly / Once weekly (same day each week)
Weight Loss Initiation 0.25mg Weekly x 4 weeks, then increase
Weight Loss Maintenance 2.4mg Weekly (after 16-week titration)
Diabetes Management 0.5-1mg Weekly
Cardiovascular Protection 0.5-1mg Weekly
Tolerability-Based 0.25-2.4mg Weekly (individualized)
Side Effects
GHRP-6
Intense hunger/increased appetite (most notable side effect)
Water retention
Tingling or numbness in extremities
Tiredness or lethargy after injection
Mild headache
Semaglutide
Nausea
Diarrhea
Vomiting
Constipation
Abdominal pain
Contraindications
Active cancer or history of cancer
Pregnancy or breastfeeding
Pituitary disorders
Diabetes (use with caution)
WADA prohibited for competitive athletes
Personal or family history of medullary thyroid cancer
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Pregnancy or breastfeeding
History of pancreatitis
Research Evidence
GHRP-6 Semaglutide
Status Well Studied FDA Approved
References 3 studies 9 studies
Latest — 2025-06
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.